Browsing Tag
Amgen
52 posts
Biocon wins U.S. launch date for Prolia and Xgeva biosimilars—Can Amgen keep investors calm?
Amgen settles with Biocon for denosumab biosimilars, paving way for Bosaya and Aukelso U.S. launch from Oct 2025. What this means for biotech and investors.
Nyrada Inc (ASX: NYR) stock draws fresh attention as investors eye trial milestones in 2025
Nyrada Inc (ASX: NYR) stock is moving on higher volumes as trial milestones near. Find out why investors are watching this biotech in 2025.
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results highlighting long-term safety and durable response in atopic dermatitis
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results showing long-term safety and durable efficacy in atopic dermatitis. Find out what comes next.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Amgen and Kyowa Kirin see breakthrough in rocatinlimab Phase 3 Trial, eyes on FDA path
Amgen and Kyowa Kirin have reported positive top-line results from the Rocatinlimab Phase 3 IGNITE trial, part of…
Amgen and AstraZeneca’s Tezspire achieves key milestone in Phase 3 nasal polyps trial
Amgen and AstraZeneca have revealed promising results from the Phase 3 Waypoint trial, demonstrating that Tezspire (tezepelumab-ekko) delivers…
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio…